De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding of the molecular mechanisms responsible for c...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Haematologica
المؤلفون الرئيسيون: Magistroni, Vera, Mauri, Mario, D’Aliberti, Deborah, Mezzatesta, Caterina, Crespiatico, Ilaria, Nava, Miriam, Fontana, Diletta, Sharma, Nitesh, Parker, Wendy, Schreiber, Andreas, Yeung, David, Pirola, Alessandra, Readelli, Sara, Massimino, Luca, Wang, Paul, Khandelwal, Praveen, Citterio, Stefania, Viltadi, Michela, Bombelli, Silvia, Rigolio, Roberta, Perego, Roberto, Boultwood, Jacqueline, Morotti, Alessandro, Saglio, Giuseppe, Kim, Dong-Wook, Branford, Susan, Gambacorti-Passerini, Carlo, Piazza, Rocco
التنسيق: Artigo
اللغة:Inglês
منشور في: Ferrata Storti Foundation 2019
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC6717574/
https://ncbi.nlm.nih.gov/pubmed/30819912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.179937
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة